Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Mitchell S von Itzstein"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Immune checkpoint inhibitors (ICIs) have revolutionized oncology treatment. However, their success is mitigated by the recognition that ICI-induced immune-related adverse events (irAEs) pose considerable challenges to patients and clinicians. These a
Externí odkaz:
https://doaj.org/article/b6e8f51070cd4f08b48ec890699dc7aa
Autor:
Jarushka Naidoo, Igor Puzanov, Paolo A Ascierto, Marc S Ernstoff, Douglas B Johnson, Fei Ye, Mitchell S von Itzstein, David E Gerber, Benjamin Switzer, Aliyah Pabani, Hannah Burnette, Run Fan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 5 (2024)
Background Artificial intelligence (AI) chatbots have become a major source of general and medical information, though their accuracy and completeness are still being assessed. Their utility to answer questions surrounding immune-related adverse even
Externí odkaz:
https://doaj.org/article/10149fdee8db4c7899ea1632bcd5d0b9
Autor:
Yang Xie, Shaheen Khan, Prithvi Raj, Edward K Wakeland, Mitchell S von Itzstein, Farjana Fattah, Jason Y Park, David Hsiehchen, Jared Ostmeyer, David E Gerber, Mary Gwin, Rodrigo Catalan
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 8 (2023)
Background Immune checkpoint inhibitor (ICI) therapies may cause unpredictable and potentially severe autoimmune toxicities termed immune-related adverse events (irAEs). Because T cells mediate ICI effects, T cell profiling may provide insight into t
Externí odkaz:
https://doaj.org/article/3479b528102c43d8a55d222dbb9e00ea
Publikováno v:
eLife, Vol 10 (2021)
Changes in MAPK signaling allow lung cancer cells to transition between lineages that respond differently to treatment.
Externí odkaz:
https://doaj.org/article/b45fbd4b11c648d38dc97fec5dcaf919
Autor:
Yang Xie, Vinita Popat, Shaheen Khan, Saad A Khan, Edward K Wakeland, Quan-Zhen Li, Murtaza Ahmed, Mitchell S von Itzstein, Thomas Sheffield, Farjana Fattah, Jason Y Park, Jessica M Saltarski, Yvonne Gloria-McCutchen, David Hsiehchen, Jared Ostmeyer, Nazima Sultana
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Background Increased body mass index (BMI) has been associated with improved response to immune checkpoint inhibitors (ICIs) in multiple cancer types. We evaluated associations between BMI, ICI dosing strategy, and clinical outcomes.Methods We abstra
Externí odkaz:
https://doaj.org/article/621df1a1a67640a2af6757144a9d4c70
Autor:
Mitchell S von Itzstein, Arjun Gupta, Kemp H Kernstine, Kristin C Mara, Sahil Khanna, David E Gerber
Publikováno v:
PLoS ONE, Vol 15, Iss 4, p e0231258 (2020)
INTRODUCTION:Advances in surgical techniques have improved clinical outcomes and decreased complications. At the same time, heightened attention to care quality has resulted in increased identification of hospital-acquired adverse events. We evaluate
Externí odkaz:
https://doaj.org/article/c6a6065b27b048bead91898bbe2e4b72
Autor:
David Hsiehchen, Abdul Rafeh Naqash, Magdalena Espinoza, Mitchell S. Von Itzstein, Alessio Cortellini, Biagio Ricciuti, Dwight H. Owen, Mehak Laharwal, Yukihiro Toi, Michael Burke, Yang Xie, David E. Gerber
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
The timing of immune-related adverse events (irAE) associated with immune checkpoint inhibitors (ICI) is highly variable. Although the development of irAE has been associated with ICI clinical benefit, how irAE timing influences this association is u
Externí odkaz:
https://doaj.org/article/314b3c66dd194bac9be88d3b95ef3bff
Autor:
Amrit S. Gonugunta, Mitchell S. Von Itzstein, David Hsiehchen, Tri Le, Sawsan Rashdan, Hui Yang, Christopher Selby, Carlos Alvarez, David E. Gerber
Publikováno v:
Clinical Lung Cancer. 24:11-17
Antibiotic exposure is associated with worse clinical outcomes in patients receiving immune checkpoint inhibitors (ICI). We analyzed antibiotic prescription patterns in lung cancer and melanoma, two malignancies in which ICI are used broadly across s
Autor:
Mary Lou Smith, Liz Garrett-Mayer, Julianne S Dieterich, Janet S. de Moor, Stacy W. Gray, Hong Zhu, Suanna S. Bruinooge, Jason Y. Park, Anh Quynh Hoang, Mitchell S. von Itzstein, David E. Gerber, Carol B. White, Andrew N. Freedman, Elda Railey, Jingsheng Yan
Publikováno v:
JCO Oncol Pract
PURPOSE: Advances in genomic techniques have led to increased use of next-generation sequencing (NGS). We evaluated the extent to which these tests guide treatment decisions. METHODS: We developed and distributed a survey assessing NGS use and outcom
Publikováno v:
Journal of Medical Case Reports. 16
Background Pseudoprogression, the initial apparent worsening of cancer prior to eventual improvement, is a documented feature of immune checkpoint inhibitor administration and presents a challenge to clinicians distinguishing true progression from ps